

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BAMBOOS HEALTH CARE HOLDINGS LIMITED

百本醫護控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8216)

CHANGE IN DIRECTORSHIP

The Board announces that, with effect from 1 March 2016:

- Professor Chan Chi Fai, Andrew (陳志輝) will resign from his office as independent non-executive director of the Company; and
- Dr Leung Yu Lung (梁裕龍) will be appointed as independent non-executive director of the Company.

The board of directors (the “**Board**”) of Bamboos Health Care Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the following changes in directorship of the Board.

Resignation of independent non-executive director of the Company

Professor Chan Chi Fai, Andrew (陳志輝) (“**Professor Chan**”) has tendered his resignation as independent non-executive director of the Company with effect from 1 March 2016 due to his decision to devote more time to his personal endeavours. Following his resignation, Professor Chan will cease to serve as a member of the audit committee, the remuneration committee, the nomination committee and the compliance committee of the Board.

Professor Chan has confirmed that he has no disagreement with the Board and that there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board wishes to express its sincere gratitude to Professor Chan for his invaluable contribution to the Group during his tenure of service.

Appointment of independent non-executive director of the Company

Dr Leung Yu Lung (梁裕龍) (“**Dr Leung**”) will be appointed as independent non-executive director of the Company with effect from 1 March 2016. Dr Leung will also serve as a member of the audit committee, the remuneration committee, the nomination committee and the compliance committee of the Board with effect from the date of his directorship with the Company.

Dr Leung, aged 44, graduated from The Chinese University of Hong Kong and holds the qualifications of BMedSc (First Class Hons, CUHK), MBChB (CUHK), FCOphth (Hong Kong), MRCS (Edinburgh) (Ophthalmology), GMC (UK), FCOphth (Hong Kong) & FHKAM (Ophthalmology), FRCOphth (London) and FRCS (Glasgow) (Ophthalmology).

Dr Leung is an ophthalmologist with diverse experience in ophthalmic clinical service, research, teaching, and administrative exposure. He was previously appointed as an Associate Consultant of the Department of Ophthalmology of Hong Kong Eye Hospital (2006–2011). Dr Leung is currently appointed as the Honorary Clinical Professor of the Department of Ophthalmology of Shantou University Medical College, the Honorary Clinical Assistant Professor of the Department of Ophthalmology & Visual Sciences of The Chinese University of Hong Kong and the Honorary Consultant and Specialist in Ophthalmology of the Department of Ophthalmology of Hong Kong Sanatorium & Hospital.

The terms of appointment of Dr Leung as an independent non-executive director of the Company will be governed by an appointment letter to be entered into with the Company pursuant to which Dr Leung will be appointed for an initial term of three years commencing from 1 March 2016, renewable automatically for successive terms of one year upon expiry of the then current term of his appointment, unless terminated in accordance with the terms of the appointment letter. Dr Leung is also subject to retirement by rotation and re-election in accordance with the articles of association of the Company.

Dr Leung will, upon his appointment, be entitled to a director’s emolument of HK\$96,000 per annum and such other benefits as may be determined by, and at the discretion of, the Board from time to time. The level of Dr Leung’s emolument was determined by the Board with reference to his experience, qualification, duties and responsibilities within the Group and the prevailing market conditions.

As at the date of this announcement, other than his independent non-executive directorship in the Company and as disclosed above, Dr Leung:

- (i) did not hold any position with the Company or other members of the Group;
- (ii) had not been a director in any listed public companies in Hong Kong or overseas in the last three years;
- (iii) did not have any relationships with any directors, senior management, substantial or controlling shareholders of the Company; and
- (iv) did not, directly or indirectly, have any interest in any shares or underlying shares in the Company pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above and so far as the Directors are aware, there is no other information in respect of the appointment of Dr Leung that is discloseable pursuant to Rules 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on the Growth Enterprise Market (“GEM”) of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”) nor there is any matter relating to his appointment that needs to be brought to the attention of the Shareholders.

The Board wishes to extend its warm welcome to Dr Leung on his appointment and for joining the Board.

By Order of the Board
Bamboos Health Care Holdings Limited
Kwan Chi Hong
Chairman

Hong Kong, 4 February 2016

As at the date of this announcement, the Board comprises two executive directors, namely Mr Kwan Chi Hong (Chairman) and Ms Hai Hiu Chu (Chief Executive Officer); one non-executive director, namely Mr Wong Kam Pui; and three independent non-executive directors, namely Mr Lam Cheung Wai, Professor Chan Chi Fai, Andrew and Dr Luk Yim Fai.

This announcement, for which the directors (the “Directors”) of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication. This announcement will also be published on the Company’s website at www.bamboos.com.hk